Total cost comparison in relapsed/refractory multiple myeloma

Medicine & Life Sciences

• Multiple Myeloma 100%
• Costs and Cost Analysis 62%
• Lenalidomide 55%
• Bortezomib 43%
• Dexamethasone 38%
• Health Care Costs 16%
• Drug Costs 14%
• Recurrence 10%
• Disease Progression 9%
• Fee Schedules 9%
• Product Labeling 8%
• Cost of Illness 7%
• Therapeutics 6%
• Health Care Outcome Assessment 3%
• Clinical Trials 3%
• Guidelines 3%
• Survival 3%
• Pharmaceutical Preparations 2%
• Population 2%

Social Sciences

• costs 56%
• adverse events 23%
• relapse 15%
• drug 8%
• fee schedule 6%
• scenario 6%
• management 6%
• economic model 5%
• physician's care 4%
• Clinical Trials 4%
• dollar 4%
• utilization 3%
• school grade 2%
• resources 1%
• evidence 1%
• literature 1%
• time 1%